Physician profile
David William Johnson
NPI 1902836174
$4,352.50
in general payments reported to CMS, 2019-2025
28 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $653 · 2021: $741 · 2022: $733 · 2023: $345 · 2024: $220 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $809.55 | 2019-2025 | Xtampza |
| Abbott Laboratories | $716.40 | 2019-2025 | Eterna, Ionicrf, Proclaim |
| Protega Pharmaceutials INC | $448.36 | 2022-2023 | Roxybond |
| Biodelivery Sciences International, INC. | $428.14 | 2019-2021 | |
| Abbvie INC. | $364.96 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $199.95 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $192.10 | 2019-2022 | |
| Indivior INC. | $151.05 | 2020-2025 | Sublocade |
| Horizon Therapeutics Plc | $131.02 | 2019-2020 | |
| Amgen INC. | $108.23 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.93 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $98.39 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $91.00 | 2022 | |
| Pfizer INC. | $84.25 | 2019-2021 | |
| Orexo US, INC. | $67.65 | 2021-2023 | Zubsolv |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $66.86 | 2021-2022 | |
| Daiichi Sankyo INC. | $60.32 | 2019 | |
| Virtus Pharmaceuticals LLC | $41.62 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.07 | 2022 | |
| Zyla Life Sciences, INC. | $24.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.08 | 2019-2020 | |
| Nevro Corp. | $23.63 | 2024 | Senza |
| Arbor Pharmaceuticals, INC. | $18.54 | 2021 | |
| Allergan, INC. | $13.95 | 2020 | |
| Scilex Pharmaceuticals INC. | $13.91 | 2020 | |
| Lilly USA, LLC | $13.10 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.70 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.